HER2 gene assessment in liquid biopsy of gastric and esophagogastric junction cancer patients qualified for surgery

[1] Gerson JN(2017)Perspectives of HER2-targeting in gastric and esophageal cancer Expert Opin Investig Drugs 26 531-540

[2] Skariah S(2012)HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment Appl Immunohistochem Mol Morphol 20 13-24

[3] Denlinger CS(2016)HER2 heterogeneity in gastric/gastroesophageal cancers: from benchside to practice World J Gastroenterol 22 5879-5887

[4] Astsaturov I(2012)Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis Ann Oncol 23 2656-2662

[5] Kunz PL(2014)Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapy World J Gastroenterol 20 12355-12358

[6] Mojtahed A(2013)Gastric cancer and trastuzumab: first biologic therapy in gastric cancer Ther Adv Med Oncol 5 143-151

[7] Fisher GA(2016)HER2 testing in gastric cancer: an update World J Gastroenterol 22 4619-4625

[8] Ford JM(2016)HER2 Testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology Arch Pathol Lab Med 140 1345-1363

[9] Chang DT(2020)Comparative analysis of HER2 copy number between plasma and tissue samples in gastric cancer using droplet digital PCR Sci Rep 10 4177-710

[10] Balise RR(2015)HER2 amplification detected in the circulating DNA of patients with gastric cancer: a retrospective pilot study Gastric Cancer 18 698-e43

[1] Gerson JN(2017)Perspectives of HER2-targeting in gastric and esophageal cancer Expert Opin Investig Drugs 26 531-540

[2] Skariah S(2012)HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment Appl Immunohistochem Mol Morphol 20 13-24

[3] Denlinger CS(2016)HER2 heterogeneity in gastric/gastroesophageal cancers: from benchside to practice World J Gastroenterol 22 5879-5887

[4] Astsaturov I(2012)Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis Ann Oncol 23 2656-2662

[5] Kunz PL(2014)Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapy World J Gastroenterol 20 12355-12358

[6] Mojtahed A(2013)Gastric cancer and trastuzumab: first biologic therapy in gastric cancer Ther Adv Med Oncol 5 143-151

[7] Fisher GA(2016)HER2 testing in gastric cancer: an update World J Gastroenterol 22 4619-4625

[8] Ford JM(2016)HER2 Testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology Arch Pathol Lab Med 140 1345-1363

[9] Chang DT(2020)Comparative analysis of HER2 copy number between plasma and tissue samples in gastric cancer using droplet digital PCR Sci Rep 10 4177-710

[10] Balise RR(2015)HER2 amplification detected in the circulating DNA of patients with gastric cancer: a retrospective pilot study Gastric Cancer 18 698-e43